These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1098 related articles for article (PubMed ID: 32751706)

  • 21. Immune checkpoint inhibition in ovarian cancer.
    Hamanishi J; Mandai M; Konishi I
    Int Immunol; 2016 Jul; 28(7):339-48. PubMed ID: 27055470
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies.
    Salama AK; Moschos SJ
    Ann Oncol; 2017 Jan; 28(1):57-74. PubMed ID: 28177433
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complete Local and Abscopal Responses from a Combination of Radiation and Nivolumab in Refractory Hodgkin's Lymphoma.
    Qin Q; Nan X; Miller T; Fisher R; Teh B; Pandita S; Farach AM; Pingali SR; Pandita RK; Butler EB; Pandita TK; Iyer SP
    Radiat Res; 2018 Sep; 190(3):322-329. PubMed ID: 29949442
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cancer immunotherapy-related adverse events: causes and challenges.
    Blidner AG; Choi J; Cooksley T; Dougan M; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Rapoport BL; Anderson R
    Support Care Cancer; 2020 Dec; 28(12):6111-6117. PubMed ID: 32857220
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Checkpoint blockade in esophagogastric cancer.
    Cohen NA; Strong VE; Janjigian YY
    J Surg Oncol; 2018 Jul; 118(1):77-85. PubMed ID: 29878357
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy.
    Goleva E; Lyubchenko T; Kraehenbuehl L; Lacouture ME; Leung DYM; Kern JA
    Ann Allergy Asthma Immunol; 2021 Jun; 126(6):630-638. PubMed ID: 33716146
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting immune checkpoints in hematological malignancies.
    Salik B; Smyth MJ; Nakamura K
    J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies.
    Park JA; Cheung NV
    Cancer Treat Rev; 2017 Jul; 58():22-33. PubMed ID: 28622628
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A QSP Model for Predicting Clinical Responses to Monotherapy, Combination and Sequential Therapy Following CTLA-4, PD-1, and PD-L1 Checkpoint Blockade.
    Milberg O; Gong C; Jafarnejad M; Bartelink IH; Wang B; Vicini P; Narwal R; Roskos L; Popel AS
    Sci Rep; 2019 Aug; 9(1):11286. PubMed ID: 31375756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer.
    Gaynor N; Crown J; Collins DM
    Semin Cancer Biol; 2022 Feb; 79():44-57. PubMed ID: 32623044
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Checkpoint inhibitors in AML: are we there yet?
    Ghosh A; Barba P; Perales MA
    Br J Haematol; 2020 Jan; 188(1):159-167. PubMed ID: 31808941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.
    Xu-Monette ZY; Zhou J; Young KH
    Blood; 2018 Jan; 131(1):68-83. PubMed ID: 29118007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytokines as potential combination agents with PD-1/PD-L1 blockade for cancer treatment.
    Rahimi Kalateh Shah Mohammad G; Ghahremanloo A; Soltani A; Fathi E; Hashemy SI
    J Cell Physiol; 2020 Jul; 235(7-8):5449-5460. PubMed ID: 31970790
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histopathologic Characterization of Myocarditis Associated With Immune Checkpoint Inhibitor Therapy.
    Sobol I; Chen CL; Mahmood SS; Borczuk AC
    Arch Pathol Lab Med; 2020 Nov; 144(11):1392-1396. PubMed ID: 32150459
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune checkpoint inhibitors for nonsmall cell lung cancer treatment.
    Chen YM
    J Chin Med Assoc; 2017 Jan; 80(1):7-14. PubMed ID: 27693088
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
    Hayashi H; Nakagawa K
    Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy of Hodgkin Lymphoma: Mobilizing the Patient's Immune Response.
    Ansell SM
    Cancer J; 2018; 24(5):249-253. PubMed ID: 30247261
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Checkpoint inhibitor immunotherapy in kidney cancer.
    Xu W; Atkins MB; McDermott DF
    Nat Rev Urol; 2020 Mar; 17(3):137-150. PubMed ID: 32020040
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The emerging role of immune checkpoint inhibition in malignant lymphoma.
    Hude I; Sasse S; Engert A; Bröckelmann PJ
    Haematologica; 2017 Jan; 102(1):30-42. PubMed ID: 27884973
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy.
    Chang X; Lu X; Guo J; Teng GJ
    Cancer Treat Rev; 2019 Mar; 74():49-60. PubMed ID: 30831375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 55.